We have developed a robust system to ensure that we create and maintain over 9,000 formulas that provide PCCA members with what they need to compound high-quality, pharmaceutically elegant customized medications for their patients — all while complying with the latest standards in pharmacy compounding. But what does that look like? What’s in a PCCA formula? Let's take a closer look.

PCCA applauds the FDA for their decision and statement about Oxitriptan, which ensures that patients with BH4 deficiency can continue to receive the compounded medications they need.

Want some clarity on USP <797> and USP <800> updates? Our August updates to PCCA Play are designed to do just that with a free presentation from PCCA Education and Training Manager Jerra Banwarth, RPh, FIACP and Eagle President Ross Caputo, PhD. In another video, subscribers to PCCA Play can watch Eagle Vice President of Operations Megan Jeffrey Liotta, MS, discuss USP <797> regulation updates.

If you want to help your pharmacy stand out in a competitive field, it’s not enough to just say that you have quality products. Here are five ways that you can translate your investment in quality into your competitive advantage.

Congratulations to Stephen Anderson, RPh, of The Apothecary, Sartell, Minnesota for being our August Profile in Personalized Medicine. These profiles celebrate members of the PCCA family who have proven to be champions of Pharmacy Compounding by providing the highest quality of service to their patients.

Compounders who use progesterone in their formulations are faced with the question, "Should I used micronized or wettable progesterone?" With the help of PCCA's Clinical Services team, we're here to help guide you through making the best decision in specific situations.

PCCA Science is at the forefront of compounding research and development. Yi Liu, PhD, a PCCA research pharmacist, walks us through a few recent and exciting developments from the PCCA Science division.

Dylan Herr, RA/QA Development Manager at Eagle, understands that the revised USP <797> chapter for sterile compounding makes significant revisions to the old chapter. In this latest article, Dyan is happy to provide you with an overview of those changes and strategies for implementing them.

The only thing that stays the same is that everything changes. This is true even when it comes to nonsterile compounding and USP <795>. PCCA Clinical Compounding Pharmacist Matt Martin, PharmD, addresses notable changes of the new USP guidelines and provides some considerations regarding implementation.

Renee Prescott, PCCA's Director of Education and Training, gives us a run down on what to be excited about at this year's International Seminar coming up in October!